A Multiple Dose Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ABT-288 in Stable Subjects With Schizophrenia.
Phase of Trial: Phase I
Latest Information Update: 23 Nov 2017
At a glance
- Drugs ABT 288 (Primary)
- Indications Schizophrenia
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Abbott Laboratories
- 19 Feb 2010 Actual end date added to 1 Dec 2009 as reported by ClinicalTrials.gov.
- 19 Feb 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 12 Dec 2009 Actual patient number 81 added as reported by ClinicalTrials.gov.